Pharmacological induction of mitochondrial biogenesis as a therapeutic strategy for the treatment of type 2 diabetes
- 1 November 2015
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 98 (1) , 16-28
Abstract
No abstract availableKeywords
This publication has 175 references indexed in Scilit:
- The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced ObesityCell Metabolism, 2012
- Lipid-Induced Mitochondrial Stress and Insulin Action in MuscleCell Metabolism, 2012
- SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial FunctionCell Metabolism, 2012
- Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in MiceCell Metabolism, 2011
- Total Skeletal Muscle PGC-1 Deficiency Uncouples Mitochondrial Derangements from Fiber Type Determination and Insulin SensitivityCell Metabolism, 2010
- Exercise training increases mitochondrial content and ex vivo mitochondrial function similarly in patients with type 2 diabetes and in control individualsDiabetologia, 2010
- Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA1c in obese type 2 diabetes patientsDiabetologia, 2009
- SirT1 Gain of Function Increases Energy Efficiency and Prevents Diabetes in MiceCell Metabolism, 2008
- Patients with type 2 diabetes have normal mitochondrial function in skeletal muscleDiabetologia, 2007
- Effect of 6-Month Calorie Restriction on Biomarkers of Longevity, Metabolic Adaptation, and Oxidative Stress in Overweight IndividualsJAMA, 2006